Publication | Open Access

Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial

Advanced Met-positive GastricFirst-line TherapyGastrointestinal OncologyMedicineMetronomic TherapyPathologyCancer TreatmentOncologyRadiation OncologyGastro-oesophageal Junction Cancer